Feb. 12 at 10:10 AM
$CPRX In July 2023 catalyst acquired an equity stake in santhera as part of a
$90 million upfront licensing deal for the north american rights to vamorolone (agamree).
shares acquired: catalyst acquired 1,414,688 of santhera's post-reverse-split ordinary shares.
ownership percentage: this holding represented approximately 11.26% of santhera's outstanding ordinary shares at the time of the transaction.
investment amount: the equity investment was valued at approximately
$15 million usd, based on a share price of CHF 9.477.
this investment is now worth
$22,94 million usd (shares acquired x CHF16.22) and
imho this genius move could cause that agamree was acquired for free as i assume that the investment will 5x from here!
